TCM
NVO

Traynor Capital Management’s Novo Nordisk NVO Stock Holding History

Traynor Capital Management’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$14M Sell
397,175
-4,958
-1% -$235K 0.82% 25
2025
Q4 		$20.5M Sell
402,133
-25,301
-6% -$1.29M 1.09% 15
2025
Q3 		$23.7M Buy
427,434
+28,135
+7% +$1.65M 1.35% 14
2025
Q2 		$27.9M Buy
399,299
+44,223
+12% +$3.01M 1.98% 10
2025
Q1 		$24.7M Buy
355,076
+34,914
+11% +$2.88M 2.08% 7
2024
Q4 		$27.5M Buy
320,162
+14,758
+5% +$1.6M 1.84% 10
2024
Q3 		$36.4M Buy
305,404
+10,019
+3% +$1.34M 2.18% 10
2024
Q2 		$42.2M Buy
295,385
+44,096
+18% +$5.84M 3.16% 7
2024
Q1 		$32.3M Buy
251,289
+33,607
+15% +$4M 2.8% 8
2023
Q4 		$22.5M Buy
217,682
+21,356
+11% +$2.11M 2.31% 9
2023
Q3 		$17.9M Buy
196,326
+51,640
+36% +$4.55M 2.24% 7
2023
Q2 		$11.7M Buy
144,686
+3,188
+2% +$260K 1.44% 13
2023
Q1 		$11.3M Buy
141,498
+1,034
+0.7% +$73.3K 1.63% 11
2022
Q4 		$9.51M Buy
140,464
+1,310
+0.9% +$76.8K 1.34% 14
2022
Q3 		$6.93M Buy
139,154
+350
+0.3% +$18.8K 1.24% 19
2022
Q2 		$7.73M Sell
138,804
-6,160
-4% -$342K 1.34% 18
2022
Q1 		$8.05M Sell
144,964
-1,252
-0.9% -$64.3K 1.04% 20
2021
Q4 		$8.19M Buy
146,216
+2,974
+2% +$161K 0.97% 22
2021
Q3 		$6.88M Buy
143,242
+5,176
+4% +$250K 0.94% 22
2021
Q2 		$5.85M Buy
138,066
+2,422
+2% +$93.9K 0.82% 28
2021
Q1 		$4.57M Buy
135,644
+3,998
+3% +$142K 0.75% 35
2020
Q4 		$4.6M Sell
131,646
-8,774
-6% -$303K 0.82% 30
2020
Q3 		$4.97M Sell
140,420
-2,460
-2% -$82K 1.14% 20
2020
Q2 		$4.68M Buy
142,880
+4,808
+3% +$153K 1.13% 19
2020
Q1 		$4.16M Sell
138,072
-8,582
-6% -$256K 1.48% 16
2019
Q4 		$4.24M Buy
146,654
+1,696
+1% +$47K 1.13% 21
2019
Q3 		$3.75M Buy
144,958
+1,186
+0.8% +$30K 1.17% 20
2019
Q2 		$3.7M Buy
143,772
+360
+0.3% +$8.9K 1.2% 18
2019
Q1 		$3.75M Buy
143,412
+1,620
+1% +$39.8K 1.26% 17
2018
Q4 		$3.27M Sell
141,792
-184
-0.1% -$4.09K 1.36% 16
2018
Q3 		$3.35M Buy
141,976
+4,252
+3% +$104K 1.09% 18
2018
Q2 		$3.22M Buy
137,724
+5,310
+4% +$126K 1.17% 17
2018
Q1 		$3.26M Buy
132,414
+3,268
+3% +$85.8K 1.32% 16
2017
Q4 		$3.46M Buy
129,146
+5,326
+4% +$135K 1.48% 12
2017
Q3 		$2.98M Buy
123,820
+1,964
+2% +$44.4K 1.42% 13
2017
Q2 		$2.53M Buy
121,856
+8,864
+8% +$179K 1.25% 15
2017
Q1 		$2.25M Buy
112,992
+5,478
+5% +$95.4K 1.26% 17
2016
Q4 		$1.92M Sell
107,514
-950
-0.9% -$17.2K 1.27% 19
2016
Q3 		$2.19M Sell
108,464
-10,228
-9% -$254K 1.55% 15
2016
Q2 		$3.22M Sell
118,692
-2,498
-2% -$68.5K 2.52% 9
2016
Q1 		$3.28M Sell
121,190
-9,724
-7% -$261K 2.62% 11
2015
Q4 		$3.8M Sell
130,914
-3,110
-2% -$86.1K 2.73% 7
2015
Q3 		$3.63M Buy
134,024
+2,390
+2% +$67.7K 3.14% 7
2015
Q2 		$3.6M Buy
131,634
+94,336
+253% +$2.65M 3.01% 7
2015
Q1 		$995K Sell
37,298
-780
-2% -$18K 0.95% 22
2014
Q4 		$805K Buy
+38,078
New +$851K 0.94% 21

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Traynor Capital Management's NVO Position: Q1 2026 in Review

Traynor Capital Management reduced its Novo Nordisk (NVO) stake by 1.2% in Q1 2026, selling an estimated $235K and leaving 397,175 shares worth $14M. The position accounts for 0.82% of the portfolio, ranked #25.

Traynor Capital Management first reported a position in NVO in Q4 2014 and has held it in 46 quarters since. The position peaked at $42.2M in Q2 2024. 1,271 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • Traynor Capital Management held 397,175 shares of Novo Nordisk worth $14M as of Q1 2026.
  • Traynor Capital Management sold 4,958 Novo Nordisk shares in Q1 2026, an estimated $235K.
  • Novo Nordisk made up 0.82% of Traynor Capital Management's portfolio in Q1 2026, its #25 holding.
  • Traynor Capital Management first reported a position in Novo Nordisk in Q4 2014 and has held it in 46 quarters since.
  • Traynor Capital Management's Novo Nordisk position peaked at $42.2M in Q2 2024.
  • 1,271 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Traynor Capital Management's 13F filing for Q1 2026, filed 15 May 2026.